Clinical Trial Update: Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update evaluating lenalidomide plus subcutaneous daratumumab versus lenalidomide plus dexamethasone in frail, untreated multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: University Hospital, Lille | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING